GlassScriptPhysician profile
Muhammad D Akhtar
NPI 1548238918
$9,250.49
in general payments reported to CMS, 2019-2025
64 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $944 · 2020: $1,193 · 2021: $1,094 · 2022: $1,269 · 2023: $1,538 · 2024: $1,503 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,727 · Education: $23.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,726.97 |
| Education | $23.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $853.88 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $697.47 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Incyte Corporation | $681.56 | 2019-2025 | Jakafi |
| Janssen Biotech, INC. | $623.89 | 2019-2025 | Talvey, Imbruvica, Darzalex |
| Lilly USA, LLC | $595.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $571.43 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $564.97 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Epizyme, INC. | $406.76 | 2020-2022 | |
| Abbvie INC. | $384.09 | 2021-2025 | Venclexta, Vraylar |
| Glaxosmithkline, LLC. | $249.43 | 2021-2025 | Trelegy Ellipta, Arexvy, Zejula |
| Janssen Pharmaceuticals, INC | $230.30 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $220.85 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $213.98 | 2019-2023 | Opdivo |
| Esperion Therapeutics, INC. | $181.17 | 2020-2025 | Nexletol |
| Pharmacyclics LLC, An Abbvie Company | $156.66 | 2019-2023 | Imbruvica |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.